Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism

Hypogonadism Clinical Trial

Official title:

Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00613288
• Other study ID #: M-20070046
• Status: Completed
• Phase: N/A
• First received: January 31, 2008
• Last updated: October 21, 2009
• Start date: September 2007
• Est. completion date: September 2009

Study information

• Verified date: October 2009
• Source: University of Aarhus
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Medicines Agency
• Study type: Interventional

Clinical Trial Summary

Testosterone(T) has known effects on many organ systems, although many of its metabolic actions are unrevealed. T is an anabolic hormone stimulating protein synthesis but this effect has barely been investigated in controlled studies. It also has lipolytic actions influencing body composition, but little is known of its regional impact on fat tissue. T affects insulin sensitivity. There is an increased incidence of hypogonadism in type 2 diabetes, and among patients with hypogonadism there is an increased incidence of type 2 diabetes. The actions of testosterone on glucose metabolism are unknown.

The purpose of this study is therefore to:

Investigate the lipolytic effect of testosterone on muscle and fat tissue. To gain insight in the intracellular mechanisms of testosterone on lipolysis and investigate possible regional differences in lipolysis and changes in body composition.

Finally to investigate the effect of short term experimental hypogonadism and acute testosterone substitution on cytokines, insulin sensitivity and protein metabolism.

The trial is a randomised double blinded cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young men will receive GnRH treatment over a 3 month period and examined on 4 occasions with various degrees of T substitution and placebo . The examinations take place at the Research Lab within the Medical Department M.

The investigations are deemed relevant to the understanding of the interrelationship between male hypogonadism and type 2 diabetes. The hypothesis is that T has beneficial effects on carbohydrate, fat and protein metabolism. The generated knowledge would therefore hopefully improve prophylaxis, screening and early treatment of both group of patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 35 Years

Eligibility

Inclusion Criteria:

• Male, age 20-35

• Normal biochemical screen and ECG

Exclusion Criteria:

• Heart disease

• BMI>25

• Diabetes

• Antecedent or present cancer

• Vascular disease

• Antecedent or present hormone treatment

• Medical treatment with known effects on fat metabolism

• Big X-ray examinations equivalent to, or more than a chest x-ray and all kinds of CT scans until 6 month before the start of the study and during the study.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Hypogonadism
• Insulin Resistance

Intervention

Drug:
• Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo
The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention. The four days will include treatment on the examination day, Day 1 with: Placebo (hypogonadism after leuprorelide injection) Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection). Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection). No treatment.

Locations

Country	Name	City	State
Denmark	Medical department M and Investigational Laboratories	Aarhus C	Jutland

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004 Jul;89(7):3313-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Testosterone influence on Insulin Sensitivity, Lipolysis and protein metabolism		4-6 month pr patient	No
Secondary	Testosterone influence on Body composition by DEXA scan, Energy expenditure by indirect Calorimetry and VO2 max test		4-6 month pr patient	No